[go: up one dir, main page]

ATE157871T1 - Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind - Google Patents

Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind

Info

Publication number
ATE157871T1
ATE157871T1 AT95107372T AT95107372T ATE157871T1 AT E157871 T1 ATE157871 T1 AT E157871T1 AT 95107372 T AT95107372 T AT 95107372T AT 95107372 T AT95107372 T AT 95107372T AT E157871 T1 ATE157871 T1 AT E157871T1
Authority
AT
Austria
Prior art keywords
therapeutic
smooth muscle
prophylactic treatment
hyperplasia
muscle cells
Prior art date
Application number
AT95107372T
Other languages
English (en)
Inventor
Kumi Yamada
Yoshikuni Tamao
Masahiro Ohshima
Norimichi Iwase
Original Assignee
Mitsubishi Chem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chem Corp filed Critical Mitsubishi Chem Corp
Application granted granted Critical
Publication of ATE157871T1 publication Critical patent/ATE157871T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95107372T 1994-05-19 1995-05-16 Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind ATE157871T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10536794 1994-05-19

Publications (1)

Publication Number Publication Date
ATE157871T1 true ATE157871T1 (de) 1997-09-15

Family

ID=14405751

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95107372T ATE157871T1 (de) 1994-05-19 1995-05-16 Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind

Country Status (9)

Country Link
US (1) US5643911A (de)
EP (1) EP0682947B1 (de)
CN (1) CN1116526A (de)
AT (1) ATE157871T1 (de)
CA (1) CA2149691A1 (de)
DE (1) DE69500673T2 (de)
DK (1) DK0682947T3 (de)
ES (1) ES2109752T3 (de)
GR (1) GR3025568T3 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716956A (en) * 1995-06-07 1998-02-10 Bearsden Bearsden Bio, Inc. Dihydrophthalazine antagonists of excitatory amino acid receptors
CN1103591C (zh) * 1996-05-22 2003-03-26 永光制药有限公司 取代的1,4,5,6-四氢哒嗪并[4,5-c]哒嗪-5-酮类化合物之药物组合物及其应用和制备方法
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US6903101B1 (en) 2000-08-10 2005-06-07 Bayer Pharmaceuticals Corporation Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
WO2003051854A1 (en) * 2001-12-11 2003-06-26 Kyowa Hakko Kogyo Co., Ltd. Thiadiazoline derivative
DE60325879D1 (de) 2002-11-08 2009-03-05 Tyco Healthcare Selbstverschliessende kanüle
US20070082910A1 (en) * 2003-04-08 2007-04-12 Mitsubishi Pharma Corporation Specific nad(p)h oxidase inhibitor
CN1774428B (zh) 2003-04-18 2010-06-16 协和发酵麒麟株式会社 M期驱动蛋白抑制剂
EP1632484A4 (de) * 2003-06-10 2008-09-03 Kyowa Hakko Kogyo Kk Thiadiazolinderivat
EP1870404A4 (de) * 2005-03-22 2010-07-14 Kyowa Hakko Kirin Co Ltd Mittel zur behandlung eines hämatopoietischen tumors
AU2006225636A1 (en) * 2005-03-22 2006-09-28 Fujifilm Corporation Therapeutic agent for solid tumor
JPWO2006137490A1 (ja) * 2005-06-24 2009-01-22 協和発酵キリン株式会社 再狭窄治療剤
US8025640B2 (en) 2008-06-27 2011-09-27 Tyco Healthcare Group Lp Pressurized surgical valve

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3738371A (en) 1970-12-11 1973-06-12 Esb Inc Cardiac pacers with source condition-responsive rate
JPS5653660A (en) 1979-10-09 1981-05-13 Mitsubishi Yuka Yakuhin Kk 4-phenylphthalazine derivative
JPS5653659A (en) 1979-10-09 1981-05-13 Mitsubishi Yuka Yakuhin Kk Blood platelet coagulation suppressing agent
JPS5748972A (en) 1980-09-10 1982-03-20 Mitsubishi Yuka Yakuhin Kk 4-phenylphthalazine derivative
JPS5738715A (en) 1980-08-18 1982-03-03 Mochida Pharmaceut Co Ltd Medical composition having activity of prohibiting artery wall from thickening
JPS60218377A (ja) 1984-04-16 1985-11-01 Mitsubishi Yuka Yakuhin Kk 4−フエニルフタラジン誘導体及びそれを有効成分とする循環改善剤
JPS60243074A (ja) 1985-04-15 1985-12-03 Mitsubishi Yuka Yakuhin Kk 4−フエニルフタラジン誘導体
ZA896851B (en) 1988-09-14 1990-06-27 Hoffmann La Roche Use of ace-inhibitors
DE3926606A1 (de) 1989-08-11 1991-02-14 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
JPH0383923A (ja) 1989-08-25 1991-04-09 Terumo Corp 中膜平滑筋細胞の遊走阻害剤
JPH03106873A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd 1―ピリジルフタラジン誘導体及びそれらを含有する血小板凝集抑制剤
JP2852538B2 (ja) 1989-09-29 1999-02-03 第一製薬株式会社 〔1,2,4〕トリアゾロ〔1,5―a〕ピリミジン誘導体
EP0449203B1 (de) 1990-03-30 1994-12-07 Mitsubishi Chemical Corporation 4-Phenylphthalazin-Derivate
JPH04211666A (ja) 1990-03-30 1992-08-03 Mitsubishi Kasei Corp 4−フェニルフタラジン誘導体
JP2999808B2 (ja) 1990-08-20 2000-01-17 第一製薬株式会社 2位置換トリアゾロピリミジン類
JPH04154720A (ja) 1990-10-16 1992-05-27 Terumo Corp カテコール誘導体及びこれを含有する血管壁肥厚防止薬
TW279162B (de) 1991-09-26 1996-06-21 Mitsubishi Chem Corp

Also Published As

Publication number Publication date
CA2149691A1 (en) 1995-11-20
CN1116526A (zh) 1996-02-14
DE69500673D1 (de) 1997-10-16
GR3025568T3 (en) 1998-03-31
US5643911A (en) 1997-07-01
DK0682947T3 (da) 1998-05-04
DE69500673T2 (de) 1998-03-19
EP0682947B1 (de) 1997-09-10
EP0682947A1 (de) 1995-11-22
ES2109752T3 (es) 1998-01-16

Similar Documents

Publication Publication Date Title
RU94045155A (ru) Способы ингибирования болезни альцгеймера
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
BG101715A (bg) Тетрациклени спиросъединения,метод за тяхното получаване и приложението им като 5нт долу 1d рецепторни антагонисти
ATE157871T1 (de) Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind
DK0490772T3 (da) 1,4-disubstituerede piperaziner, fremgangsmåde til fremstilling heraf og farmaceutiske midler, der indeholder dem
NO902800D0 (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
DE69819110D1 (de) Ein Arzneimittel zur Behandlung von Fettleibigkeit und Verbesserung des lipidmetabolismus
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
ATE265851T1 (de) Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
NO172640C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive piperazinderivater
EP0104826A3 (de) Immunomodulator und Verwendungsmethode für Immunomodulation
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
ATE183088T1 (de) Arzneimittel zur behandlung von hauterkrankungen
IT1223395B (it) Composti ad attivita' cardiovascolare
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
ATE204294T1 (de) Thiol derivate mit metallopeptidase inhibierender aktivitat
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems
ATE212842T1 (de) Quinoxalin-derivate zur behandlung von tinnitus
ATE186912T1 (de) Carbamoylpyrrolidon-derivate zur behandlung von depressionen und cerebrovasculären störungen
UA30143A (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань
TH16370A (th) สารประกอบไดแอริล

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee